Sutro Biopharma (NASDAQ:STRO) Raised to Sell at Wall Street Zen

Sutro Biopharma (NASDAQ:STRO – Get Free Report) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Monday, Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on STRO. Citigroup reissued a “market outperform” rating on shares of Sutro Biopharma in a research report on Thursday, August 13th. Weiss Ratings raised shares of Sutro Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Citizens Jmp lowered their price objective on shares of Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating for the company in a research report on Thursday, August 13th. Wells Fargo & Company initiated coverage on Sutro Biopharma in a research note on Wednesday, September 30th. They set an “overweight” rating and a $49.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $60.00 target price on shares of Sutro Biopharma in a report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $49.60.

View Our Latest Analysis on STRO

Sutro Biopharma Price Performance

Sutro Biopharma stock opened at $8.92 on Monday. The company’s 50 day simple moving average is $12.76 and its 200 day simple moving average is $22.48. Sutro Biopharma has a fifty-two week low of $7.15 and a fifty-two week high of $43.85. The firm has a market capitalization of $148.07 million, a price-to-earnings ratio of -0.75 and a beta of 1.56.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.26). The company had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $14.11 million. As a group, analysts predict that Sutro Biopharma will post -8.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Sutro Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Merck & Co. Inc. acquired a new position in Sutro Biopharma in the 2nd quarter worth $9,042,053. Seven Fleet Capital Management LP bought a new position in Sutro Biopharma during the 2nd quarter worth about $5,283,000. Perceptive Advisors LLC acquired a new stake in shares of Sutro Biopharma in the 1st quarter valued at about $17,818,000. Affinity Asset Advisors LLC raised its stake in shares of Sutro Biopharma by 42.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock valued at $26,642,000 after purchasing an additional 321,137 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Sutro Biopharma in the 2nd quarter valued at about $1,373,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Latest Sutro Biopharma News

These are some of the STRO news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its price target for Sutro Biopharma to $57, a bullish analyst signal, while maintaining its Buy rating. Sutro Biopharma Price Target Raised to $57.00
  • Positive Sentiment: HC Wainwright improved its Q4 2026 EPS estimate to a loss of $1.93 per share from a projected loss of $2.46, suggesting a less severe near-term loss outlook.
  • Negative Sentiment: The firm cut its full-year EPS forecasts substantially: to losses of $9.24 for 2027, $10.87 for 2028, $7.59 for 2029, and $7.83 for 2030. These deeper projected losses could weigh on sentiment, even though HC Wainwright retained its Buy rating.

About Sutro Biopharma

(Get Free Report)

Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.

Further Reading

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.